Should I buy or sell Palisade Bio stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PALI shares. View PALI analyst ratings or view top-rated stocks .

What is Palisade Bio's stock price target for 2024?

1 brokerages have issued 1 year target prices for Palisade Bio's shares. Their PALI share price targets range from $22.50 to $240.00. On average, they expect the company's stock price to reach $131.25 in the next year. This suggests a possible upside of 2,600.6% from the stock's current price. View analysts price targets for PALI or view top-rated stocks among Wall Street analysts .

How have PALI shares performed in 2024?

Palisade Bio's stock was trading at $8.85 at the start of the year. Since then, PALI shares have decreased by 45.1% and is now trading at $4.86. View the best growth stocks for 2024 here .

Are investors shorting Palisade Bio?

Palisade Bio saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,800 shares, a decrease of 96.0% from the March 15th total of 45,200 shares. Based on an average daily trading volume, of 181,500 shares, the short-interest ratio is presently 0.0 days. View Palisade Bio's Short Interest .

When is Palisade Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our PALI earnings forecast .

How were Palisade Bio's earnings last quarter?

Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($3.75) EPS for the quarter.

When did Palisade Bio's stock split?

Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Palisade Bio?

Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PALI

Palisade Bio (PALI) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free PALI Stock Alerts

$4.71

-0.36 (-7.10%)

(As of 04:00 PM ET)

Compare

Today's Range: $4.50
▼
$5.07
50-Day Range: $4.07
▼
$6.77
52-Week Range: $3.82
▼
$36.60

Volume: 144,693 shs
Average Volume: 569,814 shs
Market Capitalization: $4.00 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $131.25

Get Palisade Bio alerts:

Palisade Bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,600.6% Upside
$131.25 Price Target
Short Interest: Healthy
0.21% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 12 Articles This Week
Insider Trading: Acquiring Shares
$5,994 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.09 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Palisade Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Palisade Bio has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.21% of the outstanding shares of Palisade Bio have been sold short.
Short Interest Ratio / Days to Cover
Palisade Bio has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Palisade Bio has recently decreased by 96.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Palisade Bio does not currently pay a dividend.
Dividend Growth
Palisade Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PALI.

3.0

News and Social Media Coverage

News Sentiment
Palisade Bio has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Palisade Bio this week, compared to 1 article on an average week.
Search Interest
8 people have searched for PALI on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.
MarketBeat Follows
4 people have added Palisade Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Palisade Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,994.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.24% of the stock of Palisade Bio is held by insiders.
Percentage Held by Institutions
Only 11.79% of the stock of Palisade Bio is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Palisade Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Palisade Bio is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Palisade Bio has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Palisade Bio Stock (NASDAQ:PALI)

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

PALI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PALI Stock News Headlines

April 19, 2024 | benzinga.com

Looking Into Palisade Bio's Recent Short Interest

April 17, 2024 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Palisade Bio (PALI)

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 17, 2024 | americanbankingnews.com

Palisade Bio (NASDAQ:PALI) Given Buy Rating at Maxim Group

April 17, 2024 | msn.com

How Apple Car Key Works (and Why It Still Hasn’t Caught On)

April 16, 2024 | msn.com

Palisade Bio stock rallies nearly 100% on colitis drug analysis

April 16, 2024 | marketwatch.com

Palisade Bio Shares Surge 80% After Lab Study Results for Ulcerative Colitis Treatment

April 16, 2024 | msn.com

Why Palisade Bio Stock Is Soaring Today

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 16, 2024 | investorplace.com

Why Is Palisade Bio (PALI) Stock Up 57% Today?

April 16, 2024 | finance.yahoo.com

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

April 16, 2024 | globenewswire.com

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool

April 12, 2024 | uk.investing.com

Palisade Bio advances ulcerative colitis treatment to Phase 1 study

April 11, 2024 | globenewswire.com

Palisade Bio to Participate in the Virtual Investor Lunch Break Event

April 10, 2024 | msn.com

Palisade Bio stock slides 8% amid colitis drug presentation

April 10, 2024 | finance.yahoo.com

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™

April 10, 2024 | globenewswire.com

Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™

April 6, 2024 | morningstar.com

Palisade Bio Inc 7NS

April 3, 2024 | globenewswire.com

Palisade Bio Announces 1-for-15 Reverse Stock Split

March 27, 2024 | finance.yahoo.com

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

March 27, 2024 | investorplace.com

PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023

February 15, 2024 | finance.yahoo.com

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

February 15, 2024 | globenewswire.com

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

February 13, 2024 | finanznachrichten.de

Palisade Bio, Inc.: Palisade Bio Provides Corporate Update and Reiterates Guidance

February 13, 2024 | marketwatch.com

Palisade Names Donald Williams Chairman, Cuts Board Size in Half

February 13, 2024 | finance.yahoo.com

Palisade Bio Provides Corporate Update and Reiterates Guidance

February 8, 2024 | finance.yahoo.com

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

See More Headlines

Receive PALI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Palisade Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:PALI
CUSIP: N/A
CIK: 1357459
Web: www.palisadebio.com
Phone: (858) 704-4900
Fax: N/A
Employees: 12
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $131.25
High Stock Price Target: $240.00
Low Stock Price Target: $22.50
Potential Upside/Downside: +2,600.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($27.1364)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,300,000.00
Net Margins: N/A
Pretax Margin: -4,920.00%
Return on Equity: -89.68%
Return on Assets: -76.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.15
Quick Ratio: 5.15

Sales & Book Value

Annual Sales: $250,000.00
Price / Sales: 16.52
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $18.29 per share
Price / Book: 0.27

Miscellaneous

Outstanding Shares: 850,000
Free Float: 833,000
Market Cap: $4.13 million
Optionable: Not Optionable
Beta: 1.33

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Ryker Willie
Senior VP of Finance & Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PALI Stock Analysis - Frequently Asked Questions

Should I buy or sell Palisade Bio stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Palisade Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PALI shares.
View PALI analyst ratings or view top-rated stocks.
What is Palisade Bio's stock price target for 2024?: 1 brokerages have issued 1 year target prices for Palisade Bio's shares. Their PALI share price targets range from $22.50 to $240.00. On average, they expect the company's stock price to reach $131.25 in the next year. This suggests a possible upside of 2,600.6% from the stock's current price.
View analysts price targets for PALI or view top-rated stocks among Wall Street analysts.
How have PALI shares performed in 2024?: Palisade Bio's stock was trading at $8.85 at the start of the year. Since then, PALI shares have decreased by 45.1% and is now trading at $4.86.
View the best growth stocks for 2024 here.
Are investors shorting Palisade Bio?: Palisade Bio saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 1,800 shares, a decrease of 96.0% from the March 15th total of 45,200 shares. Based on an average daily trading volume, of 181,500 shares, the short-interest ratio is presently 0.0 days.
View Palisade Bio's Short Interest.

When is Palisade Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our PALI earnings forecast.
How were Palisade Bio's earnings last quarter?: Palisade Bio, Inc. (NASDAQ:PALI) released its quarterly earnings results on Tuesday, March, 26th. The company reported ($3.75) EPS for the quarter.
When did Palisade Bio's stock split?: Shares of Palisade Bio reverse split on the morning of Monday, April 8th 2024. The 1-15 reverse split was announced on Monday, April 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
How do I buy shares of Palisade Bio?: Shares of PALI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PALI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Palisade Bio (PALI) Stock Price, News & Analysis

Palisade Bio MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Palisade Bio Stock (NASDAQ:PALI)

PALI Stock Price History

PALI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PALI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™